Fundraising FoxInvus — 2022 Investments
6 investments dated 2022 · listed companies and verified rows first · show all
LifeMine is a biopharmaceutical company that uses data science and advanced methods to accelerate drug discovery and develop precision medicines across therapeutic areas.
AI & Machine LearningBiotechDeep TechCambridge, US
Gregory L. Verdine(Executive Officer, Director)Gregory Verdine, Ph.D.
BoardHingge Hsu(Executive Officer, Director)Weiqing Zhou(Executive Officer, Director)
Co-investorsARCH Venture PartnersGV (Google Ventures)RA CapitalAisling CapitalAlexandriaBezos Expeditions+7 more
A drug discovery company staffed by scientists and industry specialists focused on developing pharmaceutical candidates.
Biotech
Timur Yusufzai(Founder)inAsit Parikh(Chief Executive Officer)in
Co-investorsLifeSci Venture PartnersNextech InvestThird Rock VenturesAlexandriaCasdin CapitalCreacion Ventures+4 more
Pretzel Therapeutics develops therapeutics targeting bioenergetic dysfunction and mitochondrial disease by addressing defects in mitochondrial DNA function and gene expression.
BiotechDeep TechHealthtechMedical Devices
Michal Minczuk(Co-Founder)inGabriel Martinez(Chief Scientific Officer & Co-Founder)Claes Gustafsson(Co-Founder)Maria Falkenberg(Co-Founder)Nils-Göran Larsson(Co-Founder)Gabriel Martinez, Ph.D.(Chief Scientific Officer & Co-Founder)
Co-investorsARCH Venture PartnersCambridge Innovation CapitalEIR VenturesAngelini VenturesGU Ventures ABGV (Google Ventures)+3 more
Sironax is a biopharmaceutical company focused on the discovery and development of therapies for neurodegenerative, inflammatory and immunological, metabolic, and rare diseases.
BiotechHealthtechLongevityWaltham, US
Dr. Xiaodong Wang(Founder)Dr. Zhiyuan Zhang(Founder)
Co-investorsARCH Venture PartnersF-Prime CapitalYuanBio Venture CapitalCBC GroupEight Roads VenturesFuture Innovation+6 more
Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.
BiotechCambridge, US
Nancy Simonian(CEO)Peter Wirth(Director)Mark Alles(Director)Philip Sharp(Director)Richard A. Young(Director)Sue Gail Eckhardt(Director)
Co-investorsAisling CapitalARCH Venture PartnersQuan CapitalAlexandriaAlly Bridge GroupBain Capital+11 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.